Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 11/2019

01-11-2019 | Human Immunodeficiency Virus | Original Paper

A Pilot Study of a Mobile App to Support HIV Antiretroviral Therapy Adherence Among Men Who Have Sex with Men Who Use Stimulants

Authors: Keith J. Horvath, Sara Lammert, Richard F. MacLehose, Thu Danh, Jason V. Baker, Adam W. Carrico

Published in: AIDS and Behavior | Issue 11/2019

Login to get access

Abstract

APP+ is a theoretically-grounded mobile app intervention to improve antiretroviral (ART) adherence among men who have sex with men (MSM) who use stimulants. We assessed the feasibility and acceptability of APP+ in a six-month randomized controlled trial among a national sample of 90 MSM recruited online; secondarily, we examined changes in self-reported ART adherence by study arm. Retention at the final assessment was 82%, and acceptability ratings were comparable to other technology-based interventions. MSM in the APP+ group reported higher self-reported percentage ART adherence in the past 30 days at the four-month timepoint compared to a no-treatment control group (89.0% vs. 77.2%). However, once access to the app was removed after month four, group differences in ART adherence diminished by month six. APP+ may be a potentially promising intervention approach for MSM living with HIV who use stimulants but would require enhancements to optimize acceptability and demonstrate more sustained effects.
Literature
1.
2.
Singh S, Mitsch A, Wu B. HIV care outcomes among men who have sex with men with diagnosed HIV infection—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(37):969–74.PubMedPubMedCentral
3.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. The Lancet. 9651;372:1733–45.
4.
El-Bassel N, Shaw SA, Dasgupta A, Strathdee SA. Drug use as a driver of HIV risks: re-emerging and emerging issues. Curr Opin HIV AIDS. 2014;9(2):150–5.PubMedPubMedCentral
5.
Lansky A, Finlayson T, Johnson C, Holtzman D, Wejnert C, Mitsch A, et al. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and Hepatitis C virus infections. PLoS ONE. 2014;9(5):e97596.PubMedPubMedCentral
6.
Plankey MW, Ostrow DG, Stall R, Cox C, Li X, Peck JA, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2007;45(1):85–92.PubMedPubMedCentral
7.
Thiede H, Jenkins RA, Carey JW, Hutcheson R, Thomas KK, Stall RD, et al. Determinants of recent HIV infection among Seattle-area men who have sex with men. Am J Public Health. 2009;99(Suppl 1):S157–64.PubMedPubMedCentral
8.
Melendez-Torres GJ, Bourne A. Illicit drug use and its association with sexual risk behaviour among MSM: more questions than answers? Curr Opin Infect Dis. 2016;29(1):58–63.PubMed
9.
Zlotorzynska M, Sullivan P, Sanchez T. The annual American men’s internet survey of behaviors of men who have sex with men in the United States: 2015 key indicators report. JMIR Public Health Surveill. 2017;3(1):e13.PubMedPubMedCentral
10.
11.
Reback CJ, Fletcher JB, Shoptaw S, Grella CE. Methamphetamine and other substance use trends among street-recruited men who have sex with men, from 2008 to 2011. Drug Alcohol Depend. 2013;133(1):262–5.PubMedPubMedCentral
12.
Forrest DW, Metsch LR, LaLota M, Cardenas G, Beck DW, Jeanty Y. Crystal methamphetamine use and sexual risk behaviors among HIV-positive and HIV-negative men who have sex with men in South Florida. J Urban Health: Bull N Y Acad Med. 2010;87(3):480–5.
13.
Reback CJ, Fletcher JB. Reductions in HIV prevalence rates among substance-using men who have sex with men in Los Angeles County, 2008-2011. AIDS Educ Prev. 2014;26(5):459–70.PubMedPubMedCentral
14.
Ostrow DG, Plankey MW, Cox C, Li X, Shoptaw S, Jacobson LP, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009;51(3):349–55.PubMedPubMedCentral
15.
Carrico AW, Riley ED, Johnson MO, Charlebois ED, Neilands TB, Remien RH, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr. 2011;56(2):146–50.PubMedPubMedCentral
16.
Mayer KH, Skeer MR, O’Cleirigh C, Goshe BM, Safren SA. Factors associated with amplified HIV transmission behavior among American men who have sex with men engaged in care: implications for clinical providers. Ann Behav Med. 2014;47(2):165–71.PubMed
17.
Carrico AW, Hunt PW, Neilands TB, Dilworth SE, Martin JN, Deeks SG, et al. Stimulant use and viral suppression in the era of universal antiretroviral therapy. J Acquir Immune Defic Syndr. 2019;80(1):89–93.PubMedPubMedCentral
18.
Carrico AW. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci. 2011;88(21–22):940–7.PubMed
19.
Carrico AW, Shoptaw S, Cox C, Stall R, Li X, Ostrow DG, et al. Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67(5):508–13.PubMedPubMedCentral
20.
Adams JW, Bryant KJ, Edelman EJ, Fiellin DA, Gaither JR, Gordon AJ, et al. Association of cannabis, stimulant, and alcohol use with mortality prognosis among HIV-infected men. AIDS Behav. 2018;22(4):1341–51.PubMedPubMedCentral
21.
22.
Kurth AE, Spielberg F, Cleland CM, Lambdin B, Bangsberg DR, Frick PA, et al. Computerized counseling reduces HIV-1 viral load and sexual transmission risk: findings from a randomized controlled trial. J Acquir Immune Defic Syndr. 2014;65(5):611–20.PubMedPubMedCentral
23.
Johnson MO, Charlebois E, Morin SF, Remien RH, Chesney MA. Effects of a behavioral intervention on antiretroviral medication adherence among people living with HIV: the healthy living project randomized controlled study. J Acquir Immune Defic Syndr. 2007;46(5):574–80.PubMedPubMedCentral
24.
Milam J, Richardson JL, McCutchan A, Stoyanoff S, Weiss J, Kemper C, et al. Effect of a brief antiretroviral adherence intervention delivered by HIV care providers. J Acquir Immune Defic Syndr. 2005;40(3):356–63.PubMed
25.
Remien RH, Stirratt MJ, Dolezal C, Dognin JS, Wagner GJ, Carballo-Dieguez A, et al. Couple-focused support to improve HIV medication adherence: a randomized controlled trial. Aids. 2005;19(8):807–14.PubMed
26.
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45(6):770–8.PubMed
27.
Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42(11):1628–35.PubMed
28.
Simoni JM, Kutner BA, Horvath KJ. Opportunities and challenges of digital technology for HIV treatment and prevention. Curr HIV/AIDS Rep. 2015;12:437–40.PubMedPubMedCentral
29.
Horvath KJ, Lammert S, LeGrand S, Muessig KE, Bauermeister JA. Using technology to assess and intervene with illicit drug-using persons at risk for HIV. Curr Opin HIV AIDS. 2017;12(5):458–66.PubMedPubMedCentral
30.
Westergaard RP, Genz A, Panico K, Surkan PJ, Keruly J, Hutton HE, et al. Acceptability of a mobile health intervention to enhance HIV care coordination for patients with substance use disorders. Addict Sci Clin Pract. 2017;12(1):11.PubMedPubMedCentral
31.
Himelhoch S, Kreyenbuhl J, Palmer-Bacon J, Chu M, Brown C, Potts W. Pilot feasibility study of Heart2HAART: a smartphone application to assist with adherence among substance users living with HIV. AIDS Care. 2017;29:898–904.PubMed
32.
Glasner-Edwards S, Patrick K, Ybarra ML, Reback CJ, Rawson RA, Chokron Garneau H, et al. A cognitive behavioral therapy-based text messaging intervention versus medical management for HIV-infected substance users: study protocol for a pilot randomized trial. JMIR Res Protoc. 2016;5(2):e131.PubMedPubMedCentral
33.
Muessig KE, LeGrand S, Horvath KJ, Bauermeister JA, Hightow-Weidman LB. Recent mobile health interventions to support medication adherence among HIV-positive MSM. Curr Opin HIV AIDS. 2017;12(5):432–41.PubMedPubMedCentral
34.
Carrico AW, Zepf R, Meanley S, Batchelder A, Stall R. Critical review: when the party is over: a systematic review of behavioral interventions for substance-using men who have sex with men. J Acquir Immune Defic Syndr. 2016;73(3):299–306.PubMedPubMedCentral
35.
Burnham KE, Cruess DG, Kalichman MO, Grebler T, Cherry C, Kalichman SC. Trauma symptoms, internalized stigma, social support, and sexual risk behavior among HIV-positive gay and bisexual MSM who have sought sex partners online. AIDS Care. 2016;28(3):347–53.PubMed
36.
Wilson IB, Lee Y, Michaud J, Fowler FJ Jr, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016;20(11):2700–8.PubMedPubMedCentral
37.
Simoni J, Kurth A, Pearson C, Pantalone D, Merrill J, Frick P. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–45.PubMedPubMedCentral
38.
Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16(2):269–77.PubMed
39.
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1992;1:385–401.
40.
Zhang W, O’Brien N, Forrest JI, Salters KA, Patterson TL, Montaner JS, et al. Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS ONE. 2012;7(7):e40793.PubMedPubMedCentral
41.
Wong MD, Sarkisian CA, Davis C, Kinsler J, Cunningham WE. The association between life chaos, health care use, and health status among HIV-infected persons. J Gen Intern Med. 2007;22(9):1286–91.PubMedPubMedCentral
42.
Earnshaw VA, Smith LR, Chaudoir SR, Amico KR, Copenhaver MM. HIV stigma mechanisms and well-being among PLWH: a test of the HIV stigma framework. AIDS Behav. 2013;17(5):1785–95.PubMedPubMedCentral
43.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction. 1993;88(6):791–804.PubMed
44.
The LifeWindows Project Team. The LifeWindows information motivation behavioral skills ART adherence questionnaire (LW-IMB-AAQ). Storrs: University of Connecticut: Center for Health, Intervention, and Prevention; 2006.
45.
Brook J. A quick and dirty usability scale. In: Jordan PW, Thomas B, Weerdmeester BA, McClellend, editors. Usability Evaluation in industry. London: Taylor Francis; 1996.
46.
Sullivan PS, Driggers R, Stekler JD, Siegler A, Goldenberg T, McDougal SJ, et al. Usability and acceptability of a mobile comprehensive HIV prevention app for men who have sex with men: a pilot study. JMIR Mhealth Uhealth. 2017;5(3):e26.PubMedPubMedCentral
47.
Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276(8):637–9.PubMed
48.
Abshire M, Dinglas VD, Cajita MIA, Eakin MN, Needham DM, Himmelfarb CD. Participant retention practices in longitudinal clinical research studies with high retention rates. BMC Med Res Methodol. 2017;17(1):30.PubMedPubMedCentral
49.
Walters SJ, Bonacho dos Anjos Henriques-Cadby I, Bortolami O, Flight L, Hind D, Jacques RM, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open. 2017;7(3):76.
50.
Reback CJ, Grant DL, Fletcher JB, Branson CM, Shoptaw S, Bowers JR, et al. Text messaging reduces HIV risk behaviors among methamphetamine-using men who have sex with men. AIDS Behav. 2012;16(7):1993–2002.PubMedPubMedCentral
51.
Reback CJ, Shoptaw S. Development of an evidence-based, gay-specific cognitive behavioral therapy intervention for methamphetamine-abusing gay and bisexual men. Addict Behav. 2014;39(8):1286–91.PubMed
52.
Hirshfield S, Chiasson MA, Joseph H, Scheinmann R, Johnson WD, Remien RH, et al. An online randomized controlled trial evaluating HIV prevention digital media interventions for men who have sex with men. PLoS ONE. 2012;7(10):e46252.PubMedPubMedCentral
53.
Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2016. 2017 June 2018.
54.
Centers for Disease Control and Prevention. HIV surveillance report, 2016. 2017 March 21, 2018.
55.
Darbes L, Crepaz N, Lyles C, Kennedy G, Rutherford G. The efficacy of behavioral interventions in reducing HIV risk behaviors and incident sexually transmitted diseases in heterosexual African Americans. Aids. 2008;22(10):1177–94.PubMed
56.
57.
Reback CJ, Fletcher JB, Shoptaw S, Mansergh G. Exposure to theory-driven text messages is associated with HIV risk reduction among methamphetamine-using men who have sex with men. AIDS Behav. 2015;19(Suppl 2):130–41.PubMed
58.
Gustafson DH Sr, Landucci G, McTavish F, Kornfield R, Johnson RA, Mares ML, et al. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Trials. 2016;17(1):592.PubMedPubMedCentral
59.
Guarino H, Acosta M, Marsch LA, Xie H, Aponte-Melendez Y. A mixed-methods evaluation of the feasibility, acceptability, and preliminary efficacy of a mobile intervention for methadone maintenance clients. Psychol Addict Behav: J Soc Psychol Addict Behav. 2016;30(1):1–11.
60.
Cordova D, Alers-Rojas F, Lua FM, Bauermeister J, Nurenberg R, Ovadje L, et al. The usability and acceptability of an adolescent mHealth HIV/STI and drug abuse preventive intervention in primary care. Behav Med. 2018;44(1):36–47.PubMed
61.
Marlatt GA. Harm reduction: pragmatic strategies for managing high-risk behaviors. New York: Guilford Press; 1998.
62.
Finitsis DJ, Pellowski JA, Huedo-Medina TB, Fox MC, Kalichman SC. Visual analogue scale (VAS) measurement of antiretroviral adherence in people living with HIV (PLWH): a meta-analysis. J Behav Med. 2016;39(6):1043–55.PubMed
63.
Glick SN, Burt R, Kummer K, Tinsley J, Banta-Green CJ, Golden MR. Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. Drug Alcohol Depend. 2018;182:86–92.PubMed
64.
Sewell J, Cambiano V, Miltz A, Speakman A, Lampe FC, Phillips A, et al. Changes in recreational drug use, drug use associated with chemsex, and HIV-related behaviours, among HIV-negative men who have sex with men in London and Brighton, 2013–2016. Sex Transm Infect. 2018;94:494–501.PubMed
Metadata
Title
A Pilot Study of a Mobile App to Support HIV Antiretroviral Therapy Adherence Among Men Who Have Sex with Men Who Use Stimulants
Authors
Keith J. Horvath
Sara Lammert
Richard F. MacLehose
Thu Danh
Jason V. Baker
Adam W. Carrico
Publication date
01-11-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 11/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02597-3

Other articles of this Issue 11/2019

AIDS and Behavior 11/2019 Go to the issue

Original Paper

Evaluation of Sex Positive! A Video eHealth Intervention for Men Living with HIV

Original Paper

Correlates of Durable Viral Suppression (DVS) Among Criminal Justice-involved (CJI) Black Men Living with HIV in Louisiana

Original Paper

Gender Disparities in Traumatic Life Experiences and Antiretroviral Therapy Adherence Among People Living with HIV in South Carolina

Original Paper

Accessing Pre-exposure Prophylaxis (PrEP): Perceptions of Current and Potential PrEP Users in Birmingham, Alabama

Original Paper

HIV-Related Training and Correlates of Knowledge, HIV Screening and Prescribing of nPEP and PrEP Among Primary Care Providers in Southeast United States, 2017

Original Paper

Health Literacy and Health Outcomes in Persons Living with HIV Disease: A Systematic Review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits